Search

Your search keyword '"Waidmann, Oliver"' showing total 505 results

Search Constraints

Start Over You searched for: Author "Waidmann, Oliver" Remove constraint Author: "Waidmann, Oliver"
505 results on '"Waidmann, Oliver"'

Search Results

201. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

202. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

203. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

204. Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study

205. Colonisation with multidrugresistant bacteria is associated with increased mortality in patients with cirrhosis.

206. Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians.

207. Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study.

208. The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effects.

209. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.

210. Comparison of short‐course antibiotic therapy of 6 or less days with a longer treatment in patients with cholangitis after liver transplantation.

211. Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma.

212. Survival According to Therapy Regimen for Small Intestinal Neuroendocrine Tumors.

213. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers.

214. Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis.

215. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score.

216. Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric Cancer.

217. Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidates.

218. Einführung eines interdisziplinären Tumorboards führt zur Verbesserung der Behandlungsergebnisse von Cholangio- und Gallenblasenkarzinomen.

219. Impact of surface disinfection with hydrogen peroxide on the prevalence of vancomycin-resistant enterococci (VRE) in hospital wards.

220. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers.

221. Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE.

222. The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease.

223. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.

224. The E3 Ubiquitin Ligase Parkin Is Recruited to the 26 S Proteasome via the Proteasomal Ubiquitin Receptor Rpn13.

225. Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging.

226. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma.

227. Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels.

228. Phosphorylation of the Autophagy Receptor Optineurin Restricts Salmonella Growth.

229. Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort.

230. Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma.

231. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.

232. Tumour-specific activation of a tumour-blood transport improves the diagnostic accuracy of blood tumour markers in mice.

233. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0.

234. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion.

235. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0.

236. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion.

237. S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion.

238. Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B.

239. Site of analysis matters - Ongoing complete response to Nivolumab in a patient with HIV/HPV related metastatic anal cancer and MLH1 mutation.

240. Comparison of the Covered Self-Expandable Viatorr CX Stent with the Covered Balloon-Expandable BeGraft Peripheral Stent for Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation: a Single-Centre Retrospective Study in Patients with Variceal Bleeding.

241. Low Platelet Count Predicts Reduced Survival in Potentially Resectable Hepatocellular Carcinoma.

242. [The use of immuno-oncologic therapy in hepatocellular carcinoma in the context of liver transplantation. An interdisciplinary benefit/risk assessment].

243. Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study.

244. Molecular Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Liver Transplant Candidates.

245. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.

246. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.

247. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.

248. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer.

249. [Introduction of an interdisciplinary tumor board leads to improvement of treatment outcome of cholangiocarcinoma (bile duct cancer)].

250. [Systemic Chemotherapy of gallbladder carcinoma - simply the same as for cholangiocarcinoma?]

Catalog

Books, media, physical & digital resources